Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Seasonal Influenza Vaccine Market in Top Seven Countries – Executive Summary
2.1 Top Seven Countries Set to Grow at a Moderate CAGR of 3.9% during the Forecast Period
2.2 Increasing Government Efforts are Driving the Seasonal Influenza Vaccine Market
2.3 Novel Vaccines and New Production Technologies will Revolutionize the Seasonal Influenza Market
2.4 Major Pharmaceutical Companies’ Strong Focus on Entering the Seasonal Influenza Vaccine Market
3 Seasonal Influenza Vaccines Market in Top Seven Countries: Introduction
3.1 GBI Research Report Guidance
4 Seasonal Influenza Vaccine Market in Top Seven Countries: Market Overview
4.1 Production Cycle for Seasonal Influenza Vaccines
4.2 Seasonal Influenza Vaccine Market in Top Seven Countries
4.2.1 Vaccination Pattern
4.2.1.1 Population
4.2.1.2 Vaccination Coverage
4.2.1.3 Vaccination Coverage
4.2.1.4 Total Number of Doses
4.2.2 Total Revenue
4.3 Drivers and Restraints
4.3.1 Drivers
4.3.1.1 Threat of Pandemic Influenza
4.3.1.2 Emergence of Novel Production Technologies and Vaccines
4.3.1.3 Increase in Geriatric Population
4.3.1.4 Government Support for Vaccination
4.3.2 Restraints
4.3.2.1 Entry Barriers to the Seasonal Influenza Vaccine Market
4.3.2.2 Variable Demand
4.3.2.3 Perception of Influenza as Benign Disease in Children
5 Seasonal Influenza Vaccine Market in Top Seven Countries: Geographical Landscape
5.1 The US
5.1.1 Vaccination Pattern
5.1.1.1 Population
5.1.1.2 Vaccinated Population Coverage
5.1.1.3 Vaccination Coverage
5.1.1.4 Number of Doses per Person
5.1.1.5 Total Number of Doses
5.1.1.6 Dose Contribution
5.1.1.7 Number of Public and Private Doses
5.1.2 Vaccine Cost
5.1.3 Total Revenue
5.2 Drivers and Restraints
5.2.1 Drivers
5.2.1.1 Recommendations for Annual Seasonal Influenza Vaccination
5.2.1.2 Increasing Seasonal Influenza Awareness
5.2.1.3 Vaccination is More Convenient
5.2.1.4 Growing Elderly Population
5.2.2 Barriers
5.2.2.1 Low Contribution from the Government
5.2.2.2 High Price of Vaccine
5.3 The UK
5.3.1 Vaccination Pattern
5.3.1.1 Population
5.3.1.2 Vaccinated Coverage
5.3.1.3 Vaccination Coverage
5.3.1.4 Number of Doses per Person
5.3.1.5 Total Number of Doses
5.3.1.6 Dose Contribution
5.3.1.7 Number of Public and Private Doses
5.3.2 Vaccine Cost
5.3.3 Total Revenue
5.4 Drivers and Restraints
5.4.1 Drivers
5.4.1.1 Increasing Vaccination Coverage among Elderly Population
5.4.1.2 Government Support for Immunization
5.4.2 Restraint
5.4.2.1 Low Vaccination Coverage for Influenza in Children and Adults
5.5 France
5.5.1 Vaccination Pattern
5.5.1.1 Population
5.5.1.2 Vaccination Coverage
5.5.1.3 Vaccination Coverage
5.5.1.4 Number of Doses per Person
5.5.1.5 Total Number of Doses
5.5.1.6 Doses Contribution
5.5.1.7 Number of Public and Private Doses
5.5.2 Vaccine Cost
5.5.3 Total Revenue
5.6 Drivers and Restraints
5.6.1 Drivers
5.6.1.1 Government Support for Immunization
5.6.1.2 Low Price for the Vaccine
5.6.2 Restraints
5.6.2.1 Stagnant Vaccination Coverage
5.7 Italy
5.7.1 Vaccination Pattern
5.7.1.1 Population
5.7.1.2 Vaccination Coverage
5.7.1.3 Vaccination Coverage
5.7.1.4 Number of Doses per Person
5.7.1.5 Total Number of Doses
5.7.1.6 Dose Contribution
5.7.1.7 Number of Public and Private Doses
5.7.2 Vaccine Cost
5.7.3 Total Revenue
5.8 Drivers and Restraints
5.8.1 Drivers
5.8.1.1 Government Support for Immunization against Seasonal Influenza
5.8.1.2 Increasing Elderly Population
5.8.2 Restraints
5.8.2.1 Lack of Awareness Regarding Disease Severity and Immunization Benefits
5.9 Spain
5.9.1 Vaccination Pattern
5.9.1.1 Population
5.9.1.2 Vaccination Coverage
5.9.1.3 Vaccination Coverage
5.9.1.4 Number of Doses per Person
5.9.1.5 Total Number of Doses
5.9.1.6 Dose Contribution
5.9.1.7 Number of Public and Private Doses
5.9.2 Vaccine Cost
5.9.3 Total Revenue
5.10 Drivers and Restraints
5.10.1 Drivers
5.10.1.1 Government Support for Immunization
5.10.1.2 Increasing Elderly Population
5.10.1.3 Low Vaccine Cost
5.10.2 Restraints
5.10.2.1 Lack of Awareness Regarding Disease and Vaccination
5.11 Germany
5.11.1 Vaccination Pattern
5.11.1.1 Population
5.11.1.2 Vaccination Coverage
5.11.1.3 Vaccination Coverage
5.11.1.4 Number of Doses per Person
5.11.1.5 Total Number of Doses
5.11.1.6 Dose Contribution
5.11.1.7 Number of Public and Private Doses
5.11.2 Vaccine Cost
5.11.3 Total Revenue
5.12 Drivers and Restraints
5.12.1 Drivers
5.12.1.1 Government Support for Immunization against Seasonal Influenza
5.12.1.2 Recommendations by Healthcare Workers
5.12.1.3 Increasing Aging Population
5.12.2 Restraints
5.12.2.1 Low Vaccination Rates among Adults and Children
5.12.2.2 High Vaccine Cost
5.13 Japan
5.13.1 Vaccination Pattern
5.13.1.1 Population
5.13.1.2 Vaccinated Population Contribution
5.13.1.3 Vaccination Coverage
5.13.1.4 Number of Doses per Person
5.13.1.5 Total Number of Doses
5.13.2 Vaccine Cost
5.13.3 Total Revenue
5.14 Drivers and Restraints
5.14.1 Drivers
5.14.1.1 Influenza Immunization Program
5.14.1.2 Incidences of Pandemic Influenza
5.14.1.3 Rapidly Growing Elderly Population
5.14.1.4 Subsidized Immunization for the Elderly
5.14.2 Restraints
5.14.2.1 Non-reimbursement of Influenza Vaccination Costs
5.14.2.2 Limited Availability Period for Subsidized Vaccines
5.14.2.3 Lack of Scientific Studies Establishing Safety and Efficacy of Flu Vaccines in Japan
5.14.2.4 High Vaccine Cost
6 Seasonal Influenza Vaccine Market in Top Seven Countries: Regulatory Landscape
6.1 Registration Process and Regulations for Vaccines in the US
6.2 Registration Process and Regulations for Vaccines in the EU
6.3 Registration Process and Regulations for Vaccines in Japan
7 Seasonal Influenza Vaccine Market in Top Seven Countries: Pipeline Analysis
7.1 Summary
7.2 Research and Development Pipeline by Phase
7.3 Promising Vaccines under Clinical Development
7.3.1 Flu Q-QIV
7.3.1.1 Overview
7.3.1.2 Clinical Study Details
7.3.2 Optaflu
7.3.2.1 Overview
7.3.2.2 Clinical Study Details
7.3.3 Fluzone QIV
7.3.3.1 Overview
7.3.3.2 Clinical Study Details
7.3.4 FluBlok
7.3.4.1 Overview
7.3.4.2 Clinical Trial Details
7.3.5 Q-LAIV Flu Vac
7.3.5.1 Overview
7.3.5.2 Clinical Trial Details
8 Seasonal Influenza Vaccine Market in Top Seven Countries: Competitive Landscape
8.1 Market Share Analysis
8.2 Competitive Profiling
8.2.1 Sanofi Pasteur
8.2.1.1 Overview
8.2.1.2 Major Marketed Products
8.2.1.3 SWOT Analysis
8.2.2 GlaxoSmithKline
8.2.2.1 Overview
8.2.2.2 Major Marketed Products
8.2.2.3 SWOT Analysis
8.2.3 Novartis Vaccines
8.2.3.1 Overview
8.2.3.2 Major Marketed Products
8.2.3.3 SWOT Analysis
8.2.4 AstraZeneca
8.2.4.1 Overview
8.2.4.2 Major Marketed Products
8.2.4.3 SWOT Analysis
9 Seasonal Influenza Vaccine Market in Top Seven Countries: Strategic Consolidation
9.1 Overview
9.1.1 Segmentation by Deal Type
9.1.2 Segmentation by Year
9.2 Major Merger and Acquisition Deals, 2009–2012
9.2.1 Intrexon Acquires Neugenesis
9.2.2 Grupo Ferrer Internacional Completes Acquisition of 50% Stake in Alentia Biotech from Laboratorios Farmaceuticos
9.2.3 Nexus Merges with HX Diagnostics
9.2.4 Mymetics Acquires Virosome Biologicals
9.2.5 Abbott Laboratories Acquires Solvay Pharmaceuticals
9.2.6 Nutri Pharma Acquires a Majority Stake in Bionor Immuno
9.2.7 Johnson & Johnson Acquires Crucell
9.2.8 VBI Vaccines Acquires Epixis
9.2.9 Sanofi Pasteur Acquires Remaining 50% Joint Venture Interest in Sanofi Pasteur-Daiichi Sankyo Vaccines
9.2.10 Segmentation by Geography
9.2.11 Segmentation by Year
9.3 Major Licensing Agreements, 2009–2012
9.3.1 Baxter International Expands its Licensing Agreement with Takeda Pharma
9.3.2 AltraVax Enters into Licensing Agreement with Maxygen
9.3.3 iBio Enters into Licensing Agreement with G-Con
9.3.4 NasVax Extends its Research Agreement with Novartis
9.3.5 Protein Sciences Expands its Licensing Agreement with UMN Pharma for FluBlok and PanBlok
9.3.6 Segmentation by Geography
9.3.7 Segmentation by Year
9.4 Major Partnership Deals
9.4.1 Merck Enters into Agreement with CSL Biotherapies
9.4.2 GenVec Enters into an Agreement with SAIC-Frederick
9.4.3 UMN Pharma Enters into Co-Development Agreement with API
9.4.4 Daiichi Sankyo Forms Joint Venture with Kitasato Institute Research
9.4.5 Novartis International Enters into an Agreement with Synthetic Genomics Vaccines
9.4.6 PPD Enters into Collaboration Agreement with Southern Research Institute
9.4.7 Segmentation by Geography
9.4.8 Segmentation by Year
10 Seasonal Influenza Vaccine Market in Top Seven Countries: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Secondary Research
10.4.2 Primary Research
10.4.3 Model for Estimation of Seasonal Influenza Vaccine Market
10.5 Geographical Landscape
10.6 Pipeline Analysis
10.7 Competitive Landscape
10.8 Strategic Consolidations
10.9 Contact Us
10.10 Disclaimer